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Abstract
Introduction Angiogenesis is known to be a critical and
closely regulated step during bone formation and fracture
healing driven by a complex interaction of various cyto-
kines. Delays in bone healing or even nonunion might
therefore be associated with altered concentrations of spe-
ciWc angiogenic factors. These alterations might in turn be
reXected by changes in serum concentrations.
Method To determine physiological time courses of
angiogenic cytokines during fracture healing as well as
possible changes associated with failed consolidation, we
prospectively collected serum samples from patients who
had sustained surgical treatment for a long bone fracture.
Fifteen patients without fracture healing 4 months after sur-
gery (nonunion group) were matched to a collective of 15
patients with successful healing (union group). Serum con-
centrations of angiogenin (ANG), angiopoietin 2 (Ang-2),
basic Wbroblast growth factor (bFGF), platelet derived
growth factor AB (PDGF-AB), pleiotrophin (PTN) and
vascular endothelial growth factor (VEGF) were measured
using enzyme linked immunosorbent assays over a period
of 24 weeks.
Results Compared to reference values of healthy unin-
jured controls serum concentrations of VEGF, bFGF and
PDGF were increased in both groups. Peak concentrations
of these cytokines were reached during early fracture heal-
ing. Serum concentrations of bFGF and PDGF-AB were
signiWcantly higher in the union group at 2 and 4 weeks
after the injury when compared to the nonunion group.
Serum concentrations of ANG and Ang-2 declined
steadily from the Wrst measurement in normal healing frac-
tures, while no signiWcant changes over time could be
detected for serum concentrations of these factures in non-
union patients. PTN serum levels increased asymptotically
over the entire investigation in timely fracture healing
while no such increase could be detected during delayed
healing.
Conclusion We conclude that fracture healing in human
subjects is accompanied by distinct changes in systemic
levels of speciWc angiogenic factors. SigniWcant alterations
of these physiologic changes in patients developing a
fracture nonunion over time could be detected as early as
2 (bFGF) and 4 weeks (PDGF-AB) after initial trauma
surgery.
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Whereas angiogenesis—the sprouting of new capillaries
from pre-existing blood vessels—in cancer or inXammatory
disorders is part of a pathologic development and therefore,
potential target for therapeutic interventions, under certain
conditions it plays an indispensable role in maintaining or
restoring physical inviolability. One of these conditions is
bone formation during development or skeletal regenera-
tion after fractures. Bone formation for skeletal regenera-
tion is initiated by an inXammatory reaction and an
aggregation of mesenchymal cells at the fracture site [44].
Mesenchymal precursor cells diVerentiate into a chondro-
cyte lineage [3, 11, 22] and start deposing extracellular
matrix molecules such as collagen-2 and proteoglycans to
form the cartilage callus [19]. The cartilage callus provides
preliminary stability to the fracture zone. For transforma-
tion of the cartilage scaVold into bone tissue invasion of
new blood vessels is essential. Matrix metalloproteinases
(MMPs) cause a loosening of the extracellular matrix to
allow ingrowth of new blood vessels into the callus. This
process is stimulated by angiogenic cytokines.
Among these, crucial functions of vascular endothelial
growth factor (VEGF), basic Wbroblast growth factor
(bFGF), angiogenin (ANG), angiopoietin 2 (Ang-2), plate-
let derived growth factor AB (PDGF-AB), pleiotrophin
(PTN) have been described in the literature for regulation
of new blood vessel formation during early fracture heal-
ing. Expression analyses in animal models showed all of
these factors to be locally up-regulated during fracture heal-
ing [5, 25].
Furthermore, evidence exists, that fracture healing is not
only regulated by this local release of bioactive molecules,
but is also inXuenced by systemical changes of various
cytokines, hormones and growth factors [21]. In earlier
studies, we could show that, osteogenesis in adults is
accompanied by speciWc changes of serum concentrations
of messenger molecules [47, 48, 50]. By measuring serum
levels of endothelial stimulating angiogenic factor (ESAF)
one group was able to show an increased systemic angio-
genic activity after a tibia fracture, although they were not
able to compare their results between patients with success-
ful fracture healing and nonunion patients [23]. These
detectable changes might be attributable on one hand to the
absorption of locally acting cytokines into the bloodstream
but on the other hand might also be part of a systemic
response to the fracture in order to support osteogenesis.
Enhancement of—even heterotopic—bone formation by
inXuence of systemic parameters is a clinically well known
fact [29, 43]. In reverse a perturbed systemic regulation
might exert adverse eVects on the bone healing process,
thus leading to delayed or even nonunion. In preceding
studies we were able to show that TGF-1-concentrations
as well as serum concentrations of several members of the
matrix metalloproteinase system from nonunion patients
diVer from those with normal bone healing [14, 50]. A
recent study showed an increased systemic angiogenic
activity in response to a sustained fracture even on cellular
level with mobilization of endothelial precursor cells into
the peripheral bloodstream in human subjects after a tibial
fracture [22]. Systemic messenger molecules might also
contribute to recruitment of mesenchymal precursor cells
from distant locations to the fracture site, which was dem-
onstrated by Shirley et al. [40].
These Wndings further underline the importance of a sys-
temic view on angiogenesis during fracture healing. Better
understanding of the pathophysiological processes leading
to delayed fracture healing or nonunion might open new
diagnostic or even therapeutic approaches to disturbed frac-
ture healing. Thereby, systemic measurements represent a
convenient minimal-invasive way to study physiological or
pathological regulatory functions of angiogenic molecules
in human subjects in vivo.
Goal of this study was therefore, to determine normal
time courses of angiogenic factors as well as detection of
possible alterations during the development of a fracture
nonunion. The selection of measured angiogenic cytokines
was based on the Wndings of local importance of each factor
as well as the feasibility of detection within human serum.
Materials and methods
Recruitment parameters, sample collection schedule, the
matching process and patient demographics have already
been published in detail earlier [14].
Shortly, 137 consecutive patients receiving an osteosyn-
thetic procedure for the treatment of a long bone fracture
were enrolled prospectively in this study. For all patients,
radiographic proofs of a long bone fracture, age between 18
and 80 years as well as informed and written consent were
required prior to inclusion into the study. In order to
achieve a collective as homogenous as possible, patients
with multiple trauma, extensive soft tissue damage, open
fracture type II or III according to the Gustilo-classiWcation,
postoperative respirator ventilation for longer than 24 h,
septic complications or more than two fractures were
excluded. Further exclusion criteria, were the existence of
systemic diseases such as hypo- or hyperthyroidism, diabe-
tes mellitus, advanced liver disease, chronic inXammatory
diseases, malignancy and extreme obesity as well as long-
term medication with immunosuppressive drugs.
All enrolled patients, were invited to attend follow-up
examinations at standardized intervals: 1 and 2 weeks after
trauma, bi-weekly for the Wrst 3 months and once 6 months
after trauma. Due to the design of our study no pre-trauma123
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sample was collected between 2 and 4 days after trauma in
all patients. Reference values present data from healthy
human subjects as supplied by the kits manufacturer or
previous studies [49] and are summarized in Table 1.
If no bony consolidation of the fracture could be
detected on conventional radiographs and the patient con-
tinued to report exercise induced pain 4 months after
trauma, a computed tomography was performed. On the
basis of these Wndings, patients with radiographic and clini-
cal evidence of failed fracture healing and formation of an
atrophic nonunion were assigned to the nonunion group.
Nonunion patients underwent revision surgery including
debridement, bone autografting and reosteosynthesis given
that the standard criteria for operability were fulWlled.
A corresponding patient from the residual collective
with proper fracture healing was matched to each nonunion
group member by the following criteria: age (§5 years),
sex, localization of fracture, type of fracture (according to
the AO/ASIF-classiWcation), type of osteosynthesis and the
habit of smoking. These matched control patients com-
prised the union group. Out of the 137 enrolled patients, 17
were classiWed as suVering from fracture nonunion. Two of
these patients had to be excluded, because no matching
partner was available. Thus, 15 patients in each group could
be included in the Wnal analysis. Revision surgery for the
treatment of nonunion was never performed earlier than
4 months after the initial trauma.
Sample acquisition
Venous blood samples from all patients were collected at
follow-up examinations. Samples were drawn between 8
and 11 a.m. after an overnight fasting period. Serum was
separated from other blood components, aliquoted and
stored at ¡80°C.
Measurement of serum concentrations
Serum concentration of PTN were measured with an in-
house developed enzyme linked immunosorbent assay
(ELISA), which was performed on Nunc-Immuno Maxi-
sorp plates (Nunc, Roskilde, Denmark) that had been
coated overnight at room temperature with anti-PTN (AF-
252-PB; R&D Systems, Minneapolis, MN; 50 ng/well),
washed three times with 0.05% Tween 20 in PBS (wash-
ing buVer), blocked for 1 h at room temperature with 1%
BSA in PBS, and washed with washing buVer. Wells were
incubated for 2 h at room temperature with samples, stan-
dards, or blanks (300 l, diluted with PBS), washed three
times with washing buVer, and incubated for another 2 h
at room temperature or overnight at 4°C with biotinylated
anti-PTN (BAF-252; R&D Systems, Minneapolis, MN;
50 ng/well). After washing three times with washing
buVer, wells were incubated for 20 min at room tempera-
ture with a 1:20,000 dilution of a 1.25 mg/ml solution of
streptavidin–peroxidase (catalog no. 43-4323; Zymed,
Burlingame, CA), washed three times with washing
buVer, and then incubated for 30 min at room temperature
with 100 l of tetramethylbenzidine–H2O2 (TMB Sub-
strate kit, catalog no. 34021; Pierce, Rockford, IL). The
reaction was stopped by the addition of 50 l of 0.5 M
H2SO4, and the yellow dye was measured at an absor-
bance of 450 nm. The assay was linear for 0.05–1.5 ng of
PTN with a detection limit of »0.02 ng. Recombinant
human PTN for standard solutions was obtained from
PeproTech (Rock Hill, NJ).
Serum levels of VEGF, ANG, Ang-2, bFGF and PDGF-
AB were quantiWed on commercially available ELISA
(‘Quantikine® ELISA Kits’; R&D Systems, Minneapolis,
MN, USA). Assays were performed according to the manu-
facturer’s instructions and suggested serum dilutions. All
samples were measured in duplicates. To avoid data corrup-
tion by interassay variability, all samples from each non-
union patient and the respective matching partner were
assessed simultaneously on the same plate.
Statistical analysis
The results of 15 patients from each group were included in
the statistical analysis. A study group size of a total of 30
patients (15 patients per group) was calculated to be neces-
sary for group comparison using a pretrial power analysis
based on the results of the Wrst three pairs of patients. The
power has been calculated exemplarily for bFGF as one of
the major angiogenic cytokines of the current study.
For the detection of signiWcant changes over time the
nonparametric Friedman-test was applied. The Wilcoxon
signed rank test for paired samples was used for compari-
son between the two groups at each time point of the obser-
vation period. Results are presented as mean § standard
error of mean.
P < 0.05 was considered signiWcant. The study was con-
ducted upon formal approval of local ethics committee and
Table 1 Reference serum concentrations of the investigated
cytokines from normal human subjects
NA not available, SD standard deviation
n Mean (pg/ml) SD Range (pg/ml)
Angiogenin 40 360 NA 196–496
Angiopoietin-2 60 2,494 1,341 pg/ml 1,065–8,907
bFGF 65 2.21 NA 0–6.9
PDGF-AB 31 20.1 NA 10.5–29.5
Pleiotrophin 58 420 240 pg/ml 0–1,000
VEGF 37 220 NA 62–707123
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informed consent was obtained from all patients prior to
inclusion in the study.
Results
For all investigated factors time courses of serum concen-
trations could be determined over the entire investigation
period (Fig. 1). In patients with successful bone healing
all angiogenic factors showed signiWcant changes over
time.
Compared to the respective reference values, measured
cytokine serum levels were higher for bFGF, PDGF, PTN
and VEGF, whereas Ang-2 levels were considerably lower.
Measured values for ANG were well within the range of the
given reference.
Analysis of the time courses of the serum concentrations
revealed three diVerent types of curve progressions:
ANG and Ang-2 decreased steadily after trauma. The
second group comprises VEGF, FGF basic and PDGF-AB.
These factors reached peak concentrations 2 weeks after
fracture timely coincident with the histologically deWned
period of matrix degradation and vascularization of the car-
tilage callus with subsequent continuous decrease and
approximation to reference values. In contrast to the two
aforementioned groups, serum concentrations of PTN
increased asymptotically over time.
Fig. 1 Time courses of serum 
concentrations of angiogenic 
factors in patients with proper 
and failed fracture healing. 
* P < 0.05 for comparison 
between union and nonunion 
group; aP < 0.05 for changes 
over time within one group. 
Dashed line illustrates reference 
values
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the investigated angiogenic agents several diVerences
could be found in patients who developed a fracture non-
union: whereas Friedman-analysis revealed signiWcant
changes over time for all six cytokines in the union group,
this could not be proven for ANG and Ang-2 in nonunion
patients, though, mean values for these two factors did not
diVer greatly from those of patients with normal fracture
healing.
The peak of bFGF serum concentrations which was seen
at 2 weeks after trauma in patients with proper bone healing
was lacking in patients who developed a nonunion. This
diVerence was statistically signiWcant at this time point
(P = 0.011). In contrast to the union group where bFGF
concentrations decreased continuously after the initial peak
and leveled oV near to the reference value after 6 months, in
nonunion patients serum bFGF increased slightly at
2 months after surgery leading to signiWcant diVerences
between the groups at the end of the observation period.
In addition to changes in bFGF time courses, mean
PDGF-AB serum concentrations were lower in nonunion
patients over the entire investigation period, reaching the
level of signiWcance at 4 (P = 0.015) and 12 weeks
(P = 0.041) after trauma.
In contrast, time course of VEGF serum concentrations
in resembled each other closely in both groups with slightly
higher serum values in the nonunion collective. However,
this diVerence was not statistically signiWcant.
Compared to the constant increase of PTN over time
during the physiologic fracture healing period in unions,
serum concentrations of this protein did not deviate greatly
from the Wrst post-trauma value in the nonunion group.
Missing statistical signiWcance, the diVerence of serum con-
centrations between unions and nonunions in support of
constantly higher levels during normal fracture healing
seems at least noticeable.
Discussion
Pre-existing data, mostly derived from histological examin-
ations of tissues from experimental animal models, demon-
strated distinct stages of fracture repair, which are
characterized by the involved cellular phenotypes, compo-
sition of the extracellular matrix and expression of various
enzymes and messenger molecules [4, 28, 36, 43, 46]. For
understandable ethical reasons, multiple surgical explora-
tions of a fracture site and tissues excisions are not possible
in human subjects. However, clinical and experimental
observations suggested that the local process of bone regen-
eration is associated with systemic reactions that might
partly be attributable to the uptake of bioactive molecules
from the fracture site [8, 9, 31].
We therefore analyzed serum samples of patients for
cytokines known to be involved in osteogenesis as a surro-
gate for their local activity at the area of bone formation. In
our preceding studies, we were already able to show char-
acteristic changes in serum concentrations of various
growth factors, enzymes and hormones during diVerent
types of bone formation, such as distraction osteogenesis,
osteotomy and fracture healing as well as formation of a
fracture nonunion [14, 47, 48, 50]. One striking Wnding was
a lack of adequate TGF-1 serum concentrations in patients
without fracture healing 4 weeks after trauma when com-
pared to subjects with timely fracture healing [50].
A critical step during the process of fracture healing is
vascular ingrowth into the cartilage callus. This process
requires loosening of the collagenous matrix by proteases,
namely MMPs and is itself a prerequisite for the transfor-
mation of the soft callus into calciWed bone tissue. An
altered balance of the MMP/TIMP system in favor of prote-
olytic activity as shown in our earlier investigation may be
involved in the pathophysiological processes leading to
fracture nonunion [14]. Like the overall process of bone
formation, time and location of this angiogenic process
must also be closely regulated by cytokines, growth factors
and hormones.
To determine if the period of angiogenesis during matu-
ration of the fracture callus is also associated with an
altered systemic angiogenic activity we used this already
established methodology on angiogenic factors that are
known to be involved in the regulation of new blood vessel
formation especially during endochondral osteogenesis.
Our own current analysis focused on the proangiogenic
factors ANG, Ang-2, bFGF, PDGF-AB, PTN and VEGF.
Expression analyses in animal models showed all of these
factors to be up-regulated during fracture healing [5, 25].
VEGF
VEGF is known to be one of the major players in promot-
ing angiogenesis during bone formation [10]. It has been
shown to play a crucial role in regulating osteogenesis not
only by mediating new blood vessel formation, but also by
promoting cell diVerentiation of hypertrophic chondro-
cytes, osteoblasts, endothelial cells and osteoclasts [29].
Active VEGF is contained in the extracellular matrix of the
cartilage precursor. During matrix remodeling MMPs such
as MMP-9 degrade extracellular matrix and release VEGF.
A second pathway to an increased release of VEGF seems
to be the TGF-1 induced expression of VEGF by osteo-
blast-like cells within in the fracture callus [38] and in vitro
[7]. In our study peak levels of VEGF were present at
2 weeks after the fracture and were increased fourfold com-
pared to reference concentrations. This corresponds to the
results presented by Street et al. [41], where plasma levels123
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our earlier results on MMPs cannot easily be correlated
with the demonstrated time course of VEGF concentrations
in terms of their association in the VEGF release from
extracellular stores, comparison with TGF-1 serum con-
centrations shows a convincing analogy [14, 50]. Both
cytokines show elevated serum concentrations already at
1 week after trauma, peak levels were reached at 2 weeks
and at 4 weeks return to baseline is achieved. Although,
this correlation does not prove the dependence of VEGF
release on the stimulation of TGF-1 it suggests an associa-
tion of these two factors within the process of angiogenesis.
However, from the results of our current study showing no
signiWcant diVerence between systemic VEGF in timely
versus delayed fracture healing one can argue that, at least
at the systemic level, TGF-1 induced release of VEGF
seems not to be not disturbed during the process of delayed
fracture healing.
Basic Wbroblast growth factor (FGF basic, FGF-2, bFGF)
FGF basic was also shown to stimulate expression of
VEGF, independently from the TGF-1 pathway [39].
Stimulation of angiogenesis during bone healing by local
administration of bFGF was demonstrated in a variety of
animal studies including nonhuman primates and a clinical
application is already discussed [12, 32, 37]. However,
underlying mechanisms of bFGF mediated enhancement of
fracture healing are still unclear. As already suggested by
Saadeh et al. [39]—based on the synchronous courses of
serum concentrations during fracture healing—we suggest
a close interconnection between the three cytokines, bFGF,
VEGF and TGF-1. The initial peak serum concentration
of bFGF 2 weeks after trauma, which was missing in the
nonunion group leads to the important conclusion, that
early disruption of the angiogenic progress may hinder the
physiological process of osteogenesis.
Pleiotrophin, PTN; osteoblast stimulating factor 1, OSF-1; 
heparin-binding growth-associated molecule, HB-GAM
Pleiotrophin is a member of a newly identiWed family of
developmentally regulated, secreted, heparin-binding pro-
teins with proven angiogenic potency. It is highly
expressed during embryogenesis and plays an important
role not only in early growth and diVerentiation, but also in
tumor growth and metastasis and PTN serum levels have
been shown to correlate with tumor growth and disease
stage [20, 49]. Under physiological conditions, its expres-
sion in human adults is minimal [49]. Increased expression
could be detected in osteoarthritis. The importance of PTN
for bone development has been shown by Imai et al. [18]
since, PTN over-expression in a transgenic mice model
resulted in a phenotype characterized by increased bone
thickness. Although local expression of the angiogenic fac-
tor PTN throughout the entire process of bone regeneration
was demonstrated in rats [35], the speciWc eVect of this
molecule on osteogenesis remains controversial. For exam-
ple, PTN showed negative eVects on mouse bone defect
healing [27] and lack of PTN did not aVect normal bone
physiology in rodents [26]. Tare et al. [42] showed that
these multiple eVects of PTN on the formation of bone were
dependent on the concentration and the timing of its pres-
ence. Our results support the importance of PTN in regula-
tion of fracture healing. Compared to the relatively low
serum concentrations in non-injured adults systemic PTN
values show a prolonged increase during the long-term pro-
cess of physiological fracture healing and remodeling. In
nonunion patients serum PTN still ranged above the upper
standard deviation of the reference level. However, there
was no increase of systemic PTN over time and serum con-
centrations were constantly lower than in the union group.
Although the diVerence to patients with proper bone heal-
ing was not signiWcant, which might be due to either rela-
tively high standard deviations or insuYcient group sizes,
this tendency towards reduced systemic PTN concentra-
tions might also demonstrate an early onset of an unphysio-
logical process at least partially regulated by PTN.
Platelet derived growth factor (PDGF)
Platelet derived growth factor is known to be released from
-granules of platelets within the fracture hematoma. A
major function might be its attribute to the inXammatory
response by stimulating granule release from neutrophils
and monocytes [45]. After that Wrst step it is additionally
expressed by mature chondrocytes [16] and might also
attribute to osteogenesis by its known chemotactic and
mitogenic activity on cells of mesenchymal origin such as
Wbroblast or endothelial cells [13] and its ability to stimu-
late collagen synthesis [33]. Platelet derived growth factor
also shares a structural similarity with VEGF suggesting an
involvement in the process of angiogenesis [30]. In addi-
tion PDGF was already examined in a human in vivo study
and showed an increased gene expression during bone
repair [1]. Together with this strong evidence of an
increased expression of PDGF at the site of fracture heal-
ing, locally administered PDGF demonstrated a convincing
positive eVect on bone healing in a rabbit model of tibial
osteotomies [34].
Our data adds evidence to these Wndings: increased
expression of PDGF is mirrored in the peak serum concen-
tration at 4 weeks after sustaining of the fracture and sig-
niWcantly decreased serum concentrations are associated
with unsuccessful fracture healing. It is worth mentioning,
that at the same time point TGF-1 concentrations were123
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similar regulatory functions or even co-regulation of PDGF
and TGF-1 during early steps of fracture repair [50].
Angiogenin (ANG)
Angiogenin belongs to the pancreatic RNase superfamily
and is a potent inducer of new blood vessel formation. Sim-
ilar to VEGF, ANG seems to be involved in early stages of
bone healing. It exerts its activity by binding to actin and
thereby raising the proteolytic activity of plasminogen and
tissue plasminogen activator. Main target of proteolysis are
extracellular matrix molecules and basement membranes.
Degradation of these structures enables ingrowths of newly
formed blood vessels [2, 17]. Actions of ANG within the
fracture healing process are not yet well-investigated. From
our study, results with maximum serum concentrations
within the Wrst week we conclude that its main period of
action seems to be the initial stages of the osteogenic pro-
cess. As suggested elsewhere [6], ANG can be seen as a
marker of endothelial damage caused for example by the
trauma during surgery which might explain is continuous
decrease during fracture repair. Nonunion formation did not
signiWcantly alter ANG serum concentrations.
Angiopoietin-2 (Ang-2)
In growing human bone, Ang-2 was shown to be co-
expressed with VEGF with maximum levels of expression
at the sites of hypertrophic cartilage in endochondral bone
formation [15]. Furthermore, it seems to be under a con-
joint control of TNF- signaling together with MMPs
which underlines the association of matrix degradation and
angiogenesis during endochondral osteogenesis [25].
Interestingly serum analysis showed an early maximum of
Ang-2 concentrations, even before matrix turnover or
hypertrophic chondrocytes can be expected within the soft
callus. Future research might therefore focus on additional
actions of this molecule at early stages of the fracture healing
process. Co-expression of Ang-2 with VEGF might be
reXected in the pathophysiological process of fracture
nonunion. Together with VEGF and in contrast to all other
investigated angiogenic factors, Ang-2 was elevated in
patients with unsuccessful fracture healing. Although, a
clear tendency was recognizable, diVerences did not reach
the level of signiWcance at any given time point.
Taken together our study results underline the strong
association of the local process of angiogenesis during
fracture healing with the systemic activity of angiogenic
cytokines. The speciWc time courses of the investigated
molecules can be correlated to the histologically deWned
stages of fracture repair in general and especially during
vascularization of the cartilage callus. Major Wndings of our
current study are signiWcantly decreased serum concentra-
tions of bFGF and PDGF in patients with unsuccessful
bone healing which could be detected during fracture repair
as early as 2 and 4 weeks after trauma. Markedly, although,
not signiWcantly decreased serum values of PTN in delayed
fracture repair presented an additional interesting Wnding.
However, care has to be taken when interpreting the results
in terms of a generally decreased angiogenic activity in
delayed fracture healing. It must be emphasized that
because this is an association study, the measured factors
truly are serum markers and no direct cause eVect relation-
ship between their function in vivo and in vitro can be
established by the study. Further, serum concentrations of
other angiogenic factors like VEGF, ANG and Ang-2 were
not signiWcantly altered by the process of delayed bone
healing. Disadvantages of our model are already described
in detail in our preceding publications [14]. Most of these
cutbacks are based on the limitations that apply when corre-
lating systemic to local concentrations. In addition to the
concentration of the substance at the point of interest its
systemic concentration can be inXuenced, among others, by
the rate of uptake into the bloodstream, protein binding,
degradation or inactivation herein. As a systemic release of
osteogenic and angiogenic factors is known to contribute to
osteogenesis—such as, excessive bone formation following
traumatic brain injury—it has also to be considered that not
only uptake from the fracture site but also a release at a dis-
tant site might contribute to the measured serum concentra-
tion. Furthermore, care should be taken not to over-
interpret 24 week values in nonunion patients: due to the
revision surgery which was performed at non-standardized
time points later than 16 weeks after trauma the sample col-
lective is rather inhomogeneous and certainly not easily
comparable to patients without a secondary operation.
An additional drawback of our survey might be the lack
of a true pre-operative baseline value. Of course, the ideal
way to study changes in bone turnover would be compari-
son between pre- and post-fracture samples. This study
design has, however, not been feasible in our clinical set-
ting. Using a large cohort from the Malmö OPRA (osteopo-
rosis prospective risk assessment) study Ivaska et al. [19]
were the Wrst to analyze pre- versus post-fracture serum
values in elderly women. The authors focussed on typical
bone formation and resorption markers like osteocalcin,
type I collagen telopeptides and collagen pro-peptides
revealing no signiWcant alterations between pre- and post-
fracture serum levels when sampling was performed within
4–6 h after injury. Thereafter, and up to 1 year after sur-
gery, the post-fracture samples varied signiWcantly from the
pre-fracture status and—due to the conclusions of this
study—should not be used as baseline values. No compara-
ble data for pre- and post-fracture serum concentrations of
the factors measured in our recent survey exist so far in the123
996 Arch Orthop Trauma Surg (2009) 129:989–997literature. In our current study, the Wrst sample was
obtained within a range of up to 4 days after the injury.
Therefore, we found it not adequate to pronounce the Wrst
postoperative serum sample as reliable baseline value and
focussed the illustration of our data on mean absolute
serum values along the observational period. For both illus-
tration and comparison reasons we—instead—referred our
results to a one-time measurement of serum samples in
larger groups of normal healthy adult human subjects
known from the literature and pronounced these data as
reference values.
Nevertheless, the presented data are of signiWcant scien-
tiWc importance because we were able to show for the Wrst
time an analysis of systemic angiogenic factors in human
subjects in vivo during bone regeneration. Due to their
descriptive nature we cannot—based on our data—contrib-
ute to the elucidation of underlying mechanisms and
biochemical pathways involved in angiogenesis, but we
can provide a solid base when interpreting mechanistic data
from animal studies in terms of their transferability to the
human body. However, when performing such comparisons
it has to be considered that fracture consolidation in small
rodents is usually achieved within 3 weeks indicating that
similar stages of the osteogenic processes are reached con-
siderably earlier than in human subjects.
Further, from our data, it seems certainly overconWdent
to argue in terms of bFGF and PDGF-AB as predictive fac-
tors for delayed or failed fracture healing or to draw conclu-
sions about clinical relevance. However, it is of high
interest that signiWcantly decreased concentrations of these
two angiogenic factors can be detected in patients develop-
ing delayed fracture healing later on as early as 2 and
4 weeks after trauma. It might be worthwhile to further
investigate systemic occurrence of these factors at these
speciWc time points in larger surveys.
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